Журнал неврологии и неврологии

  • ISSN: 2171-6625
  • Индекс Хирша журнала: 17
  • Оценка цитируемости журнала: 4.43
  • Импакт-фактор журнала: 3.38
Индексировано в
  • Open J Gate
  • Журнал GenamicsSeek
  • Глобальный импакт-фактор (GIF)
  • Китайская национальная инфраструктура знаний (CNKI)
  • Справочник индексации исследовательских журналов (DRJI)
  • OCLC- WorldCat
  • Вызов запроса
  • Импакт-фактор научного журнала (SJIF)
  • Евро Паб
  • Google Scholar
  • Секретные лаборатории поисковых систем
Поделиться этой страницей

Абстрактный

Severe Guillain-Barré Syndrome Following Shingrix® Vaccine Administration

Rina Yadav*, Drew Hundley and Lannie Cation

Guillain-Barré syndrome (GBS) is a rare life threatening acute polyradiculoneuropathy with variable clinical presentations, including weakness, paresthesias, diminished deep tendon reflexes, hyponatremia, dysautonomia, and a cytoalbuminological dissociation on cerebral spinal fluid (CSF) analysis. The exact etiology remains unknown but is thought to occur as a post-infective immunemediated process. Vaccines and illnesses, including H1N1 Swine Flu vaccine, pneumococcal vaccine, Campylobacter jejuni bacteria, cytomegalovirus, and herpes zoster virus, have been associated with GBS. One vaccine that has not been identified to cause GBS is the newly released Shingrix® vaccine for herpes zoster infection prevention. We present a case of severe GBS following Shingrix® vaccine immunization.